---
document_datetime: 2025-12-02 07:00:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xultophy.html
document_name: xultophy.html
version: success
processing_time: 0.134127
conversion_datetime: 2025-12-28 00:37:52.226336
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xultophy

[RSS](/en/individual-human-medicine.xml/65871)

##### Authorised

This medicine is authorised for use in the European Union

insulin degludec / liraglutide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xultophy](#news-on)
- [Preventing medication errors](#preventing-medication-errors-1124)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xultophy is a medicine that is used for the treatment of type 2 diabetes. Together with diet and exercise, Xultophy is added to treatment with diabetes medicines taken by mouth when these medicines, alone or with other injections, have not controlled blood glucose (sugar) levels.

The active substances in Xultophy are insulin degludec and liraglutide.

Expand section

Collapse section

## How is Xultophy used?

Xultophy is available as pre-filled disposable pens and can only be obtained with a prescription. It is given as an injection under the skin of the thigh, the upper arm or the abdomen (belly). The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the medicine work less well than expected. Patients can inject themselves with Xultophy if they have been trained appropriately.

Xultophy is given once a day, preferably at the same time each day. The dose is adjusted individually for each patient, and the patient's blood glucose should be regularly tested to find the lowest effective dose.

For more information about using Xultophy, see the package leaflet or contact your doctor or pharmacist.

## How does Xultophy work?

Type 2 diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose, or the body is unable to use insulin effectively. One of the active substances in Xultophy, insulin degludec, is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced. Insulin degludec is slightly different from human insulin as it is absorbed more slowly and regularly by the body after an injection and it works for a long time.

The other active substance in Xultophy, liraglutide, belongs to the class of diabetes medicines known as GLP-1 agonists. It acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

## What benefits of Xultophy have been shown in studies?

Once-daily injection of Xultophy has been shown to be of benefit in controlling blood glucose in three main studies involving 2,514 patients with type 2 diabetes. In all studies, the main measure of effectiveness was the change after 6 months of treatment in the level in the blood of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.

- The first study involved 1,663 patients whose diabetes was not adequately controlled with the diabetes medicines metformin or metformin and pioglitazone taken by mouth. Adding Xultophy to their treatment was compared with adding either of its active substances, insulin degludec or liraglutide. The average HbA1c level, which was 8.3% at the start, fell to 6.4% after 26 weeks of treatment with Xultophy, compared with 6.9% and 7.0% respectively with insulin degludec and liraglutide.
- The second study involved 413 patients whose blood glucose was not adequately controlled by insulin and metformin with or without other diabetes medicines taken by mouth. Treatment with Xultophy and metformin was compared with treatment using insulin degludec and metformin. Average HbA1c at the start was 8.7% in the Xultophy group, and fell after 26 weeks of treatment to 6.9%. In the group using insulin degludec it fell from 8.8% to 8.0%.
- The third study involved 438 patients whose blood glucose was not adequately controlled by a combination of a GLP-1 agonist (liraglutide or exenatide) and metformin with or without other diabetes medicines taken by mouth. Patients in the study either continued with their current treatment or received Xultophy instead of the GLP-1 agonist. Average HbA1c was 7.8% before patients started to receive Xultophy, and fell after 26 weeks of treatment to 6.4%. In the group that kept on receiving the GLP-1 agonist, it fell from 7.7% to 7.4%.

The majority of patients treated with Xultophy in these studies achieved control of their blood glucose (HbA1c below 7.0%) and many achieved HbA1c below 6.5%.

## What are the risks associated with Xultophy?

The most common side effect with Xultophy (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose). Side effects on the digestive system occurred in up to 1 in 10 patients and included nausea (feeling sick), diarrhoea, vomiting, constipation, dyspepsia (indigestion), gastritis (inflammation of the stomach), abdominal pain (stomach ache), flatulence (wind), gastroesophageal reflux disease (passage of stomach acid back up towards the mouth), and distension (swelling) of the belly. For the full list of side effects and restrictions with Xultophy, see the package leaflet.

## Why is Xultophy approved?

The European Medicines Agency decided that Xultophy's benefits are greater than its risks and it can be authorised for use in the EU. Adding this medicine to other diabetes medicines offers better control of blood glucose and having an alternative treatment option is valuable in individualising treatment.

## What measures are being taken to ensure the safe and effective use of Xultophy?

The company that markets Xultophy will provide educational materials for healthcare professionals, explaining how to use the medicine safely, so as to reduce the risk of medication errors.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xultophy have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xultophy are continuously monitored. Side effects reported with Xultophy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xultophy

Xultophy received a marketing authorisation valid throughout the EU on 18 September 2014.

Xultophy : EPAR - Medicine overview

Reference Number: EMA/462053/2014

English (EN) (83.69 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 13/07/2018

[View](/en/documents/overview/xultophy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-329)

български (BG) (111.78 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/bg/documents/overview/xultophy-epar-medicine-overview_bg.pdf)

español (ES) (83.43 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/es/documents/overview/xultophy-epar-medicine-overview_es.pdf)

čeština (CS) (110.62 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/cs/documents/overview/xultophy-epar-medicine-overview_cs.pdf)

dansk (DA) (82.6 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/da/documents/overview/xultophy-epar-medicine-overview_da.pdf)

Deutsch (DE) (84.35 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/de/documents/overview/xultophy-epar-medicine-overview_de.pdf)

eesti keel (ET) (81.81 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/et/documents/overview/xultophy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (119.51 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/el/documents/overview/xultophy-epar-medicine-overview_el.pdf)

français (FR) (84.02 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/fr/documents/overview/xultophy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (105.97 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/hr/documents/overview/xultophy-epar-medicine-overview_hr.pdf)

italiano (IT) (83.19 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/it/documents/overview/xultophy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (107.65 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/lv/documents/overview/xultophy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (106.83 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/lt/documents/overview/xultophy-epar-medicine-overview_lt.pdf)

magyar (HU) (103.93 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/hu/documents/overview/xultophy-epar-medicine-overview_hu.pdf)

Malti (MT) (111.43 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/mt/documents/overview/xultophy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (82.88 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/nl/documents/overview/xultophy-epar-medicine-overview_nl.pdf)

polski (PL) (109.97 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/pl/documents/overview/xultophy-epar-medicine-overview_pl.pdf)

português (PT) (83.46 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/pt/documents/overview/xultophy-epar-medicine-overview_pt.pdf)

română (RO) (115.1 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/ro/documents/overview/xultophy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (109.96 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/sk/documents/overview/xultophy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (102.87 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/sl/documents/overview/xultophy-epar-medicine-overview_sl.pdf)

Suomi (FI) (82.6 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/fi/documents/overview/xultophy-epar-medicine-overview_fi.pdf)

svenska (SV) (82.97 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

13/07/2018

[View](/sv/documents/overview/xultophy-epar-medicine-overview_sv.pdf)

Xultophy : EPAR - Risk-management-plan summary

Reference Number: EMA/467911/2014

English (EN) (68.8 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 21/11/2014

[View](/en/documents/rmp-summary/xultophy-epar-risk-management-plan-summary_en.pdf)

## Product information

Xultophy : EPAR - Product Information

English (EN) (556.19 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 28/11/2024

[View](/en/documents/product-information/xultophy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-297)

български (BG) (757.86 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/bg/documents/product-information/xultophy-epar-product-information_bg.pdf)

español (ES) (612.28 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/es/documents/product-information/xultophy-epar-product-information_es.pdf)

čeština (CS) (719.94 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/cs/documents/product-information/xultophy-epar-product-information_cs.pdf)

dansk (DA) (590.08 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/da/documents/product-information/xultophy-epar-product-information_da.pdf)

Deutsch (DE) (657.13 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/de/documents/product-information/xultophy-epar-product-information_de.pdf)

eesti keel (ET) (613.22 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/et/documents/product-information/xultophy-epar-product-information_et.pdf)

ελληνικά (EL) (767.04 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/el/documents/product-information/xultophy-epar-product-information_el.pdf)

français (FR) (630.43 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/fr/documents/product-information/xultophy-epar-product-information_fr.pdf)

hrvatski (HR) (700.64 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/hr/documents/product-information/xultophy-epar-product-information_hr.pdf)

íslenska (IS) (596.91 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/is/documents/product-information/xultophy-epar-product-information_is.pdf)

italiano (IT) (608.46 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/it/documents/product-information/xultophy-epar-product-information_it.pdf)

latviešu valoda (LV) (706.89 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/lv/documents/product-information/xultophy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (771.05 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/lt/documents/product-information/xultophy-epar-product-information_lt.pdf)

magyar (HU) (750.07 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/hu/documents/product-information/xultophy-epar-product-information_hu.pdf)

Malti (MT) (755.58 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/mt/documents/product-information/xultophy-epar-product-information_mt.pdf)

Nederlands (NL) (663.66 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/nl/documents/product-information/xultophy-epar-product-information_nl.pdf)

norsk (NO) (577.83 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/no/documents/product-information/xultophy-epar-product-information_no.pdf)

polski (PL) (750.74 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/pl/documents/product-information/xultophy-epar-product-information_pl.pdf)

português (PT) (615.54 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/pt/documents/product-information/xultophy-epar-product-information_pt.pdf)

română (RO) (717.4 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/ro/documents/product-information/xultophy-epar-product-information_ro.pdf)

slovenčina (SK) (697.49 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/sk/documents/product-information/xultophy-epar-product-information_sk.pdf)

slovenščina (SL) (708.49 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/sl/documents/product-information/xultophy-epar-product-information_sl.pdf)

Suomi (FI) (592.11 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/fi/documents/product-information/xultophy-epar-product-information_fi.pdf)

svenska (SV) (584.35 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

28/11/2024

[View](/sv/documents/product-information/xultophy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG-1796 25/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xultophy : EPAR - All Authorised presentations

English (EN) (31.16 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 25/08/2023

[View](/en/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-473)

български (BG) (56.71 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/bg/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.18 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/es/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.72 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/cs/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.04 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/da/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (25.94 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/de/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.03 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/et/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.93 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/el/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_el.pdf)

français (FR) (26.09 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/fr/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.77 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/hr/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (27.27 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/is/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.61 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/it/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.99 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/lv/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (49.76 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/lt/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.93 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/hu/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (42.42 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/mt/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.49 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/nl/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.15 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/no/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.35 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/pl/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_pl.pdf)

português (PT) (28.48 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/pt/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_pt.pdf)

română (RO) (47.95 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/ro/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (71.25 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/sk/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.02 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/sl/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (26.06 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/fi/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.3 KB - PDF)

**First published:**

21/11/2014

**Last updated:**

25/08/2023

[View](/sv/documents/all-authorised-presentations/xultophy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xultophy Active substance

- insulin degludec
- liraglutide

International non-proprietary name (INN) or common name

- insulin degludec
- liraglutide

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10AE56

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/002647 Marketing authorisation holder

Novo Nordisk A/S

Novo Alle

Opinion adopted 25/07/2014 Marketing authorisation issued 18/09/2014 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xultophy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (229.86 KB - PDF)

**First published:** 13/05/2015

**Last updated:** 28/11/2024

[View](/en/documents/procedural-steps-after/xultophy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xultophy-H-C-002647-II-0023 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/380783/2018

English (EN) (2.21 MB - PDF)

**First published:** 13/07/2018

**Last updated:** 13/07/2018

[View](/en/documents/variation-report/xultophy-h-c-002647-ii-0023-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xultophy II/23

Adopted

Reference Number: EMA/CHMP/250993/2018

English (EN) (68.77 KB - PDF)

**First published:** 27/04/2018

**Last updated:** 27/04/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xultophy-ii23_en.pdf)

Xultophy-PSUSA-00010272-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/493797/2017

English (EN) (105.57 KB - PDF)

**First published:** 02/08/2017

**Last updated:** 02/08/2017

[View](/en/documents/scientific-conclusion/xultophy-psusa-00010272-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xultophy-H-C-PSUSA-00010272-201603 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/19627/2017

English (EN) (62.4 KB - PDF)

**First published:** 12/01/2017

**Last updated:** 12/01/2017

[View](/en/documents/scientific-conclusion/xultophy-h-c-psusa-00010272-201603-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xultophy-H-C-2647-II-0002 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/403340/2015

English (EN) (1.99 MB - PDF)

**First published:** 20/08/2015

**Last updated:** 20/08/2015

[View](/en/documents/variation-report/xultophy-h-c-2647-ii-0002-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Xultophy

Adopted

Reference Number: EMA/CHMP/332827/2015

English (EN) (67.32 KB - PDF)

**First published:** 22/05/2015

**Last updated:** 22/05/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xultophy_en.pdf)

## Initial marketing authorisation documents

Xultophy : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/369341/2014

English (EN) (1.66 MB - PDF)

**First published:** 21/11/2014

**Last updated:** 21/11/2014

[View](/en/documents/assessment-report/xultophy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xultophy

Adopted

Reference Number: EMA/CHMP/424921/2014

English (EN) (69.63 KB - PDF)

**First published:** 25/07/2014

**Last updated:** 25/07/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xultophy_en.pdf)

#### News on Xultophy

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2018) 27/04/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2015) 22/05/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2014) 25/07/2014

#### Preventing medication errors

Insulin and a non-insulin active substance: guidance on prevention of medication errors

Reference Number: EMA/134144/2015

English (EN) (74.51 KB - PDF)

**First published:** 27/11/2015

[View](/en/documents/medication-error/insulin-non-insulin-active-substance-guidance-prevention-medication-errors_en.pdf)

[Other languages (22)](#file-language-dropdown-298)

български (BG) (103.69 KB - PDF)

**First published:**

27/11/2015

[View](/bg/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_bg.pdf)

español (ES) (82.17 KB - PDF)

**First published:**

27/11/2015

[View](/es/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_es.pdf)

čeština (CS) (99.99 KB - PDF)

**First published:**

27/11/2015

[View](/cs/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_cs.pdf)

dansk (DA) (81.21 KB - PDF)

**First published:**

27/11/2015

[View](/da/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_da.pdf)

Deutsch (DE) (83.31 KB - PDF)

**First published:**

27/11/2015

[View](/de/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_de.pdf)

eesti keel (ET) (81.4 KB - PDF)

**First published:**

27/11/2015

[View](/et/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_et.pdf)

ελληνικά (EL) (104.01 KB - PDF)

**First published:**

27/11/2015

[View](/el/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_el.pdf)

français (FR) (82.72 KB - PDF)

**First published:**

27/11/2015

[View](/fr/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_fr.pdf)

hrvatski (HR) (95.21 KB - PDF)

**First published:**

27/11/2015

[View](/hr/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_hr.pdf)

italiano (IT) (81.97 KB - PDF)

**First published:**

27/11/2015

[View](/it/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_it.pdf)

latviešu valoda (LV) (99.98 KB - PDF)

**First published:**

27/11/2015

[View](/lv/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_lv.pdf)

lietuvių kalba (LT) (101.66 KB - PDF)

**First published:**

27/11/2015

[View](/lt/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_lt.pdf)

magyar (HU) (95.27 KB - PDF)

**First published:**

27/11/2015

[View](/hu/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_hu.pdf)

Malti (MT) (102 KB - PDF)

**First published:**

27/11/2015

[View](/mt/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_mt.pdf)

Nederlands (NL) (81.95 KB - PDF)

**First published:**

27/11/2015

[View](/nl/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_nl.pdf)

polski (PL) (96.84 KB - PDF)

**First published:**

27/11/2015

[View](/pl/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_pl.pdf)

português (PT) (82.34 KB - PDF)

**First published:**

27/11/2015

[View](/pt/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_pt.pdf)

română (RO) (101 KB - PDF)

**First published:**

27/11/2015

[View](/ro/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_ro.pdf)

slovenčina (SK) (99.52 KB - PDF)

**First published:**

27/11/2015

[View](/sk/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_sk.pdf)

slovenščina (SL) (97.36 KB - PDF)

**First published:**

27/11/2015

[View](/sl/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_sl.pdf)

Suomi (FI) (81.7 KB - PDF)

**First published:**

27/11/2015

[View](/fi/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_fi.pdf)

svenska (SV) (82.05 KB - PDF)

**First published:**

27/11/2015

[View](/sv/documents/medication-error/insulin-and-non-insulin-active-substance-guidance-prevention-medication-errors_sv.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/11/2024

## Share this page

[Back to top](#main-content)